Page 127 - TD-4-1

Tumor Discovery Pyrotinib and capecitabine in HER2-negative recurrence

doi: 10.1016/S1470-2045(21)00716-6 25. Wang RX, Chen S, Jin X, Chen CM, Shao ZM. Weekly
paclitaxel plus carboplatin with or without trastuzumab as
16. Yin Y, Li W, Huang X, et al. Abstract P1-11-16: Treatment
with tyrosine kinase inhibitors (TKIs) in HER2-positive neoadjuvant chemotherapy for HER2-positive breast cancer:
metastatic breast cancer after trastuzumab emtansine Loss of HER2 amplification and its impact on response and
(T-DM1) failure: A real-world study. Cancer Res. 2023;83:P1- prognosis. Breast Cancer Res Treat. 2017;161(2):259-267.
11-16. doi: 10.1007/s10549-016-4064-9
17. Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-Update 26. Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-
and clarification: From the RECIST committee. Eur J Cancer. targeted therapies in cancer: A systematic review. Biomark
2016;62:132-137. Res. 2024;12(1):16.
doi: 10.1016/j.ejca.2016.03.081 doi: 10.1186/s40364-024-00565-1
18. Baliu-Pique M, Pandiella A, Ocana A. Breast cancer 27. Graeser M, Gluz O. HER2+ early breast cancer: From
heterogeneity and response to novel therapeutics. Cancers escalation via targeted and post-neoadjuvant treatment to
(Basel). 2020;12(11):3271. de-escalation. Breast Care (Basel). 2023;18(6):455-463.
doi: 10.3390/cancers12113271 doi: 10.1159/000534670
19. Curigliano G, Burstein HJ, Gnant M, et al. Understanding 28. Loibl S, Huang CS, Mano MS, et al. Adjuvant trastuzumab
breast cancer complexity to improve patient outcomes: emtansine in HER2-positive breast cancer patients with
The St Gallen International Consensus Conference for the HER2-negative residual invasive disease in KATHERINE.
Primary Therapy of Individuals with Early Breast Cancer NPJ Breast Cancer. 2022;8(1):106.
2023. Ann Oncol. 2023;34(11):970-986.
doi: 10.1038/s41523-022-00477-z
doi: 10.1016/j.annonc.2023.08.017
29. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan
20. Buchholz TA, Ali S, Hunt KK. Multidisciplinary in previously treated HER2-low advanced breast cancer.
management of locoregional recurrent breast cancer. J Clin N Engl J Med. 2022;387(1):9-20.
Oncol 2020;38(20):2321-2328.
doi: 10.1056/NEJMoa2203690
doi: 10.1200/JCO.19.02806
30. Yamashita T, Sohn JH, Tokunaga E, et al. Trastuzumab
21. Fehm T, Muller V, Aktas B, et al. HER2 status of circulating deruxtecan versus treatment of physician’s choice in previously
tumor cells in patients with metastatic breast cancer: A treated Asian patients with HER2-low unresectable/
prospective, multicenter trial. Breast Cancer Res Treat. metastatic breast cancer: Subgroup analysis of the DESTINY-
2010;124(2):403-412. Breast04 study. Breast Cancer. 2024;31:858-868.
doi: 10.1007/s10549-010-1163-x doi: 10.1007/s12282-024-01600-7
22. Jacot W, Cottu P, Berger F, et al. Actionability of HER2- 31. Gourd E. Pyrotinib shows activity in metastatic breast
amplified circulating tumor cells in HER2-negative cancer. Lancet Oncol. 2017;18(11):e643.
metastatic breast cancer: The CirCe T-DM1 trial. Breast doi: 10.1016/S1470-2045(17)30755-6
Cancer Res. 2019;21(1):121.
32. Jacobson A. Pyrotinib improves survival in previously
doi: 10.1186/s13058-019-1215-z
treated HER2-positive metastatic breast cancer. Oncologist.
23. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5 ESO-ESMO 2022;27(Suppl 1):S5-S6.
th
international consensus guidelines for advanced breast doi: 10.1093/oncolo/oyac013
cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649.
33. Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib
doi: 10.1016/j.annonc.2020.09.010
combined with capecitabine in HER2-positive metastatic
24. Li J, Wang X, Wang S, et al. Expert consensus on the clinical breast cancer with prior Taxanes, anthracyclines, and/or
diagnosis and targeted therapy of HER2 breast cancer (2023 trastuzumab: A randomized, phase II study. J Clin Oncol.
edition). Transl Breast Cancer Res. 2022;3:30. 2019;37(29):2610-2619.
doi: 10.21037/tbcr-22-48 doi: 10.1200/JCO.19.00108

Volume 4 Issue 1 (2025) 119 doi: 10.36922/td.4093